Roswell Park Cancer Institute has joined with all the top cancer centers across the nation in issuing a statement urging for increased HPV vaccination for the prevention of cancer. Recognizing that insufficient vaccination is a public health threat, these leading institutions have called upon the nation’s physicians, parents and young adults to take advantage of this rare opportunity to prevent many types of cancer.

A research team from the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute (RPCI) has discovered a new class of small-molecule compounds that are good candidates for development of novel targeted therapies in the treatment of leukemia and lymphoma.

Researchers in the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute (RPCI) offer greater clarity of how a novel class of cancer-targeting agents called BET (Bromodomain and Extra-Terminal) inhibitors stimulate cell death in laboratory models of human cancers, specifically B-cell lymphomas.

Roswell Park Cancer Institute (RPCI) scientists report a novel enzyme inhibitor, Pevonedistat, demonstrated effectiveness in the laboratory against Mantle Cell Lymphoma (MCL), a rare and aggressive subtype of non-Hodgkin Lymphoma.